Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
1.1100 x 1 1.1400 x 1
Post-market by (Cboe BZX)
1.1200 +0.0200 (+1.82%) 04/07/25 [NASDAQ]
1.1100 x 1 1.1400 x 1
Post-market 1.1398 +0.0198 (+1.77%) 16:34 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9901
Day High
1.1300
Open 1.0300
Previous Close 1.1000 1.1000
Volume 340,600 340,600
Avg Vol 348,685 348,685
Stochastic %K 2.32% 2.32%
Weighted Alpha -91.92 -91.92
5-Day Change -0.2400 (-17.65%) -0.2400 (-17.65%)
52-Week Range 0.9901 - 800.0000 0.9901 - 800.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,239
  • Shares Outstanding, K 2,944
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,850 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9901 +13.12%
on 04/07/25
Period Open: 2.6500
4.6000 -75.65%
on 03/19/25
-1.5300 (-57.74%)
since 03/07/25
3-Month
0.9901 +13.12%
on 04/07/25
Period Open: 5.5450
9.5000 -88.21%
on 02/14/25
-4.4250 (-79.80%)
since 01/07/25
52-Week
0.9901 +13.12%
on 04/07/25
Period Open: 646.5000
800.0000 -99.86%
on 05/24/24
-645.3800 (-99.83%)
since 04/05/24

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D...

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company has one year of cash to fund operations

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary...

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq...

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Cash on hand provides over one year of runway to fund expected operations

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management...

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry...

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Webcast presentation Wednesday, February 26th at 3:20 PM CET

CNSP : 1.1200 (+1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will...

CNSP : 1.1200 (+1.82%)

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 1.3099
2nd Resistance Point 1.2199
1st Resistance Point 1.1700
Last Price 1.1200
1st Support Level 1.0301
2nd Support Level 0.9401
3rd Support Level 0.8902

See More

52-Week High 800.0000
Fibonacci 61.8% 494.7782
Fibonacci 50% 400.4951
Fibonacci 38.2% 306.2119
Last Price 1.1200
52-Week Low 0.9901

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades